Meanwhile, people with overweight or obesity lost up to 11.3% more weight than placebo by week 36 with a novel GLP-1 agonist ...

Kelley Bruns said she is concerned that if something happens to their health in the next year, they could go bankrupt. While ...

A third-generation PCSK9 inhibitor, lerodalcibep is indicated as an adjunct to diet and exercise to reduce LDL cholesterol in ...

In November, the Trump administration resurrected a Most Favored Nation (MFN) reference pricing policy, which would tie drug ...

An interventional cardiologist from Alaska -- recently arrested for allegedly possessing child pornography and fired from his ...

The FDA rarely uses its authority to pull dangerous medical devices off the market and is so poorly staffed that it's ...

At the recent American Society of Hematology (ASH) meeting, researchers presented early data from a phase II study evaluating ...

Overall, 71.8% (61.5% confirmed) of patients had partial responses to either of two dose levels of pumitamig plus ...

At the San Antonio Breast Cancer Symposium, researchers presented findings on Clarity BCR, a multimodal multitask ...

Kyverna Therapeutics announced positive topline data from a phase II trial of mivocabtagene autoleucel, a chimeric antigen ...

Under a program designed to accelerate the approval of products that could address key national priorities, the FDA awarded a ...